美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Scribe Therapeutics, Inc.

21.65

+6.6544.33%

盘后：22.000.3500+1.62%16:20 EDT

成交量：97.93万

成交额：2,273.25万

市值：3.50亿

市盈率：-8.76

高：25.49

开：25.00

低：21.00

收：15.00

52周最高：25.49

52周最低：21.00

股本：1,618.20万

流通股本：715.00万

量比：- -

换手率：13.70%

股息：- -

股息率：- -

每股收益(TTM):-2.4728

净资产收益率：--

总资产收益率：--

市净率：-2.21

市盈率(LYR):- -

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Scribe Therapeutics, Inc.

交易所：

NASDAQ

成立时间：

2017

员工人数：

89

公司地址：

1150 Marina Village Pkwy,Alameda,California,United States

官网：

http://www.scribetx.com

邮编：

94501

电话：

传真：

- -

简介：

Scribe Therapeutics, Inc.于2017年6月30日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司，致力于研发专用的体内CRISPR技术，旨在通过疾病预防和持久的治疗干预来延长健康寿命。公司正着力开发其技术，用于治疗影响数百万人的常见疾病，尤其关注那些存在巨大未满足需求和沉重临床负担的流行疾病。公司专注于心血管和代谢疾病，其初期项目旨在解决动脉粥样硬化性心血管疾病的关键驱动因素。公司正在设计基于CRISPR的基因药物，力求使其具有良好的耐受性、有效性、持久性和可扩展性，从而将治疗模式从症状驱动的干预和慢性病管理转变为人群层面的预防。公司的主要候选产品利用其高度工程化的表观遗传沉默技术，旨在实现持久有效的LDL-C降低，且不会造成永久性基因改变。

董事

名称

职位

Benjamin L. Oakes

Chairman of the Board and Chief Executive Officer and Director and President

Behzad Aghazadeh

Director

Carl L. Gordon

Director

James Watson

Director

股东

名称

职位

Benjamin L. Oakes

Chairman of the Board and Chief Executive Officer and Director and President

David L. Parrot

Chief Financial Officer

Svetlana Lucas

Chief Business Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/SCTX/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","market":"US","secType":"STK","nameCN":"Scribe Therapeutics, Inc.","latestPrice":21.65,"timestamp":1784923200000,"preClose":15,"halted":0,"volume":979324,"hourTrading":{"tag":"盘后","latestPrice":22,"preClose":21.65,"latestTime":"16:20 EDT","volume":319,"amount":6967.183938,"timestamp":1784924444879,"change":0.35,"changeRate":0.016166,"amplitude":0.050346},"delay":0,"changeRate":0.44333333333333325,"floatShares":7150000,"shares":16182010,"eps":-2.472814,"marketStatus":"盘后交易","change":6.65,"latestTime":"07-24 16:21:15 EDT","open":25,"high":25.49,"low":21,"amount":22732484.9007,"amplitude":0.299333,"askPrice":22.41,"askSize":1,"bidPrice":21.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.472814,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784937600000},"marketStatusCode":4,"adr":0,"listingDate":1784865600000,"exchange":"NASDAQ","adjPreClose":15,"postHourTrading":{"tag":"盘后","latestPrice":22,"preClose":21.65,"latestTime":"16:20 EDT","volume":319,"amount":6967.183938,"timestamp":1784924444879,"change":0.35,"changeRate":0.016166,"amplitude":0.050346},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","floatShares":7150000,"roa":"--","roe":"--","lyrEps":0,"shares":16182010,"dividePrice":0,"high":25.49,"amplitude":0.299333,"preClose":15,"low":21,"week52Low":21,"pbRate":"-2.21","psRate":"9.66","week52High":25.49,"institutionHeld":0,"latestPrice":21.65,"committee":0.980198,"eps":-2.472814,"divideRate":0,"volume":979324,"delay":0,"ttmEps":-2.472814,"open":25,"prevYearClose":15,"prevWeekClose":15,"prevMonthClose":15,"prevQuarterClose":15,"fiveDayClose":15,"twentyDayClose":15,"sixtyDayClose":15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCTX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SCTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SCTX","date":"2026-07-23","current":-6.065964,"percent":1,"low":-6.340558,"twenty":-6.340558,"median":-6.340558,"eighty":-6.340558,"high":-6.340558,"avg":-6.340558,"sd":0,"marketCap":226548140},"quantilePoints":[{"date":"2026-07-23","current":-6.340558,"twenty":-6.340558,"median":-6.340558,"eighty":-6.340558,"marketCap":226548140}],"updateTime":1784885171747},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":642070737,"yearFounded":2017,"employeeNum":89,"address":"1150 Marina Village Pkwy,Alameda,California,United States","zipCode":"94501","officePhone":"510 626 8587"},"stockCompanyDetail":{"websiteUrl":"http://www.scribetx.com","compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.034},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1639},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Scribe Therapeutics, Inc.于2017年6月30日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司，致力于研发专用的体内CRISPR技术，旨在通过疾病预防和持久的治疗干预来延长健康寿命。公司正着力开发其技术，用于治疗影响数百万人的常见疾病，尤其关注那些存在巨大未满足需求和沉重临床负担的流行疾病。公司专注于心血管和代谢疾病，其初期项目旨在解决动脉粥样硬化性心血管疾病的关键驱动因素。公司正在设计基于CRISPR的基因药物，力求使其具有良好的耐受性、有效性、持久性和可扩展性，从而将治疗模式从症状驱动的干预和慢性病管理转变为人群层面的预防。公司的主要候选产品利用其高度工程化的表观遗传沉默技术，旨在实现持久有效的LDL-C降低，且不会造成永久性基因改变。","exchange":"NASDAQ","name":"Scribe Therapeutics, Inc.","nameEN":"Scribe Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":{"directors":[{"name":"Benjamin L. Oakes","position":"Chairman of the Board and Chief Executive Officer and Director and President"},{"name":"Behzad Aghazadeh","position":"Director"},{"name":"Carl L. Gordon","position":"Director"},{"name":"James Watson","position":"Director"}],"executives":[{"name":"Benjamin L. Oakes","position":"Chairman of the Board and Chief Executive Officer and Director and President"},{"name":"David L. Parrot","position":"Chief Financial Officer"},{"name":"Svetlana Lucas","position":"Chief Business Officer"}]}}}